IRVINE, Calif., August 16, 2022 /PRNewswire/ — Lotus Bio-Technologies Development Corp. (OTC: LBTD) is pleased to announce today that the company has begun the process of changing its name from Lotus Bio-Technology Development Corp. in Boomerang Corporation.
Regarding the name change, CEO Christopher Hoyt said, “This new name more closely reflects the accessible and personalized nature of our current and future business model which aims to empower users by making healthcare easily accessible, customizable and controllable.
Boomerang uses a similar business model to EverlyWell (currently valued at $2.9 billion) and Hims & Hers, Inc. (currently valued at $1.2 billion). Boomerang provides test kits directly to users that include self-sampling devices. The user then returns their sample to one of Boomerang’s labs via a return label for testing and receives their results digitally along with a personalized wellness plan based on the results. Boomerang currently offers testing for men’s health, women’s health, sexual health, and COVID-19.
Boomerang saw an opportunity to reinvent healthcare by moving diagnostic tests to the comfort of home and giving users a path forward based on their results. With industry-leading at-home diagnostic testing, customizable wellness plans and strategic partnerships, Boomerang is uniquely positioned to become a leader in the growing billion-dollar digital health market. .
More information about the company can be found at: boomerangkit.com
Safe Harbor Statement: This press release contains “forward-looking statements.” Although the forward-looking statements contained in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those discussed in these statements. forward-looking statements.
Readers are urged to carefully review and consider the various disclosures made by LBTD in our reports filed with the Securities and Exchange Commission, including risk factors that attempt to inform interested parties of the risks that may affect our business, our financial condition, our results of operations. and cash flows. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those expected or projected. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We undertake no obligation to update any forward-looking statements to reflect any event or circumstance that may occur after the date of this release.
David Ottesstadcreative director
View original content: https://www.prnewswire.com/news-releases/lotus-bio-technology-development-corp-inc-initiates-company-name-change-301607074.html